USPTO serial 79250207
VETTER-JECT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 19, 2022
- Examiner
- AGREDA, SAMANTHA LEIGH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with VETTER-JECT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Vetter Pharma-Fertigung GmbH & Co. KG
DE
Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG
DE
Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG
DE
Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
M. Scott Alprin
M. Scott Alprin Alprin Law Offices, P.C.5 Pinehurst Circle, N.W.Washington, DC 20015UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and medicines for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; pharmaceutical solutions for oral administration in the nature of sterile aseptic solutions, namely in the form of tablets, pills, capsules, drops, medical juice and medical syrup, all for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; injectable pharmaceuticals in the nature of antibody solutions, biologicals, peptides, polypeptides, proteins, enzymes, nucleic acids, coagulation factors, interferons, phosphonates and bisphosphonates, growth factors, hormones, hormoneantagonists, insulin, heparins, low molecular heparins and sulfur hexafluoride, all for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; eyedrops, contact lens solutions; medicated compresses; medical plasters, materials for dressings in the nature of bandages, wadding and gauze; filled medical injection devices, in particular syringes and instruments for injections, injectors, auto-injectors and single-chamber and dual-chamber disposable syringes, all sold filled with pharmaceutical preparations for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia | ACTIVE | — |
| 010 | Empty medical injection devices, in particular syringes and instruments for injections, injectors, auto-injectors and single-chamber and dual-chamber disposable syringes, all sold empty; medicine containers for administering medicines, of glass and/or plastic in the nature of medical syringes, injectors, auto-injectors, disposable syringes and disposable cannulae; syringe holders being containers specially adapted for holding medical syringes; medical syringes, disposable syringes, and disposable cannulae sold either individually or in combination, all for medical purposes | ACTIVE | — |
| 039 | Bottling services, namely, bottling of liquid and solid substances, in particular of pharmaceuticals, medicines and solutions | ACTIVE | — |
| 042 | Development of syringes and instruments for injections, injectors and packaging for the aforesaid goods; laboratory tests in the nature of scientific testing in the fields of chemical, physics and process engineering; product development and conducting of scientific tests in the fields of pharmacological and microbiological processes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
- Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
- Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 039
- Other trademarks in Class 042
- Similar marks named VETTER-JECT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 14, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 22, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 22, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 19, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 19, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 19, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 9, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 3, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 3, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 13, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 13, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 13, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 27, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 26, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 25, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 25, 2022 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Sep 27, 2021 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| Sep 27, 2021 | GNCF | CONTINUATION OF FINAL REFUSAL E-MAILED | — |
| Sep 27, 2021 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Jul 28, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 16, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 28, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 28, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 2, 2020 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Mar 12, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 12, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 12, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 10, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 10, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 10, 2020 | ALIE | ASSIGNED TO LIE | — |
| Mar 5, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 5, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 5, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 4, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 6, 2019 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Nov 29, 2019 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Sep 5, 2019 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 5, 2019 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 5, 2019 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 13, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 13, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 13, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 2, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 13, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 12, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 5, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 4, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 1, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 28, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 28, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 24, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |